Brief: Biovie Initiates Sunrise-Pd Clinical Trial Assessing Bezisterim In Early Parkinson’S Disease With First Patient Enrolled
16/04/2025 13:27
April 16 (Reuters) - BioVie Inc BIVI.O: BIOVIE INITIATES SUNRISE-PD CLINICAL TRIAL ASSESSING BEZISTERIM IN EARLY PARKINSON’S DISEASE WITH FIRST PATIENT ENROLLED BIOVIE INC - TOPLINE DATA EXPECTED IN LATE 2025 OR EARLY 2026 Source text: ID:nGNX79w2KG Further company coverage: BIVI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioVie
See all newsBrief: Biovie Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Option Therapeutics Files For IPO Of 2.3 Million Shares Of Common Stock - SEC Filing
Brief: Biovie Completes Enrollment In Phase 2 Sunrise-Pd Trial In Early Parkinson’S Disease
Brief: Biovie Announces Pricing Of $12 Million Public Offering
Brief: Biovie Initiates Sunrise-Pd Clinical Trial Assessing Bezisterim In Early Parkinson’S Disease With First Patient Enrolled